Gastrointestinal Tolerability of Once-Weekly Dulaglutide 3.0 mg and 4.5 mg: A Post Hoc Analysis of the Incidence and Prevalence of Nausea, Vomiting, and Diarrhea in AWARD-11

ConclusionsThe tolerability profiles of dulaglutide 3.0  mg and 4.5 mg were consistent with that of the 1.5-mg dose. Patients experiencing GI events were most likely to do so within 2 weeks of treatment initiation, and few patients experienced a new GI event after escalating to the 3.0-mg or 4.5-mg dose. Severe events were infrequent, and when they di d occur, no relationship with dose at time of event was observed.Supplementary file1 (MP4 33880 kb)
Source: Diabetes Therapy - Category: Endocrinology Source Type: research